A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma

OBJECTIVES: TPI 287 is a synthetic taxane derivative with structural modifications allowing for central nervous system (CNS) penetration and potential circumvention of multi-drug resistance efflux pump mechanisms. The objective of this Phase I study was to determine the maximum tolerated dose (MTD)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Melanoma Res
Main Authors: McQuade, Jennifer L., Posada, Liberty P., Lecagoonporn, Srisuda, Cain, Suzanne, Bassett, Roland L., Patel, Sapna P., Hwu, Wen-Jen, Hwu, Patrick, Davies, Michael A., Bedikian, Agop Y., Amaria, Rodabe N.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5336360/
https://ncbi.nlm.nih.gov/pubmed/27540836
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CMR.0000000000000296
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados